Why OnCusp Therapeutics’ CFO hire matters for its CDH6 antibody-drug conjugate strategy
CDH6 ADCs are heating up. OnCusp Therapeutics now needs capital discipline to turn CUSP06 promise into clinical and investor credibility.
Travere Therapeutics’ $475 million raise puts spotlight on rare disease execution risk
Rare disease pipelines need time and cash. Travere’s $475 million debt deal shows how biotech balance sheets are being rebuilt.